FR2790955B1 - Utilisation d'oligonucleotides stabilises comme principe actif antitumoral - Google Patents

Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Info

Publication number
FR2790955B1
FR2790955B1 FR9903433A FR9903433A FR2790955B1 FR 2790955 B1 FR2790955 B1 FR 2790955B1 FR 9903433 A FR9903433 A FR 9903433A FR 9903433 A FR9903433 A FR 9903433A FR 2790955 B1 FR2790955 B1 FR 2790955B1
Authority
FR
France
Prior art keywords
active ingredient
stabilized oligonucleotides
tumor active
oligonucleotides
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9903433A
Other languages
English (en)
French (fr)
Other versions
FR2790955A1 (fr
Inventor
Antoine Carpentier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9903433A priority Critical patent/FR2790955B1/fr
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Priority to AU33006/00A priority patent/AU3300600A/en
Priority to EP00910993A priority patent/EP1162982B9/fr
Priority to DK00910993T priority patent/DK1162982T3/da
Priority to ES00910993T priority patent/ES2235839T3/es
Priority to PT00910993T priority patent/PT1162982E/pt
Priority to CA002371990A priority patent/CA2371990A1/fr
Priority to JP2000606246A priority patent/JP2002539265A/ja
Priority to PCT/FR2000/000676 priority patent/WO2000056342A2/fr
Priority to AT00910993T priority patent/ATE288759T1/de
Priority to US09/937,057 priority patent/US7700569B1/en
Priority to DE60018050T priority patent/DE60018050T2/de
Publication of FR2790955A1 publication Critical patent/FR2790955A1/fr
Priority to US09/967,881 priority patent/US7108844B2/en
Application granted granted Critical
Publication of FR2790955B1 publication Critical patent/FR2790955B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9903433A 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral Expired - Fee Related FR2790955B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US09/937,057 US7700569B1 (en) 1999-03-19 2000-03-17 Use of stabilised oligonucleotides for preparing a medicine with antitumor activity
DK00910993T DK1162982T3 (da) 1999-03-19 2000-03-17 Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
ES00910993T ES2235839T3 (es) 1999-03-19 2000-03-17 Uso de oligonucleotidos estabilizados para la preparacion de un medicamento de accion antitumoral.
PT00910993T PT1162982E (pt) 1999-03-19 2000-03-17 Utilizacao de oligonucleotidos estabilizados pata a preparacao de um meicamento com accao anti-tumor
CA002371990A CA2371990A1 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
AU33006/00A AU3300600A (en) 1999-03-19 2000-03-17 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity
PCT/FR2000/000676 WO2000056342A2 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
AT00910993T ATE288759T1 (de) 1999-03-19 2000-03-17 Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln
EP00910993A EP1162982B9 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
DE60018050T DE60018050T2 (de) 1999-03-19 2000-03-17 VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn
JP2000606246A JP2002539265A (ja) 1999-03-19 2000-03-17 抗腫瘍活性を有する薬剤を製造するための安定化オリゴヌクレオチドの使用
US09/967,881 US7108844B2 (en) 1999-03-19 2001-09-28 Use of stabilized oligonucleotides for preparing a medicament with antitumor activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Publications (2)

Publication Number Publication Date
FR2790955A1 FR2790955A1 (fr) 2000-09-22
FR2790955B1 true FR2790955B1 (fr) 2003-01-17

Family

ID=9543401

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9903433A Expired - Fee Related FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Country Status (12)

Country Link
US (2) US7700569B1 (enExample)
EP (1) EP1162982B9 (enExample)
JP (1) JP2002539265A (enExample)
AT (1) ATE288759T1 (enExample)
AU (1) AU3300600A (enExample)
CA (1) CA2371990A1 (enExample)
DE (1) DE60018050T2 (enExample)
DK (1) DK1162982T3 (enExample)
ES (1) ES2235839T3 (enExample)
FR (1) FR2790955B1 (enExample)
PT (1) PT1162982E (enExample)
WO (1) WO2000056342A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AU783344B2 (en) 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
AU2004280143A1 (en) * 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
AU2005266225A1 (en) * 2004-06-25 2006-02-02 Centre National De La Recherche Scientifique Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
EP1649859A1 (fr) * 2004-10-22 2006-04-26 Institut Gustave Roussy Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US20130210896A1 (en) * 2011-11-09 2013-08-15 City Of Hope Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
BR112017002629A2 (pt) 2014-08-15 2018-02-20 Adynxx, Inc. decoys de oligonucleotídeo para o tratamento de dor
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
US12377142B2 (en) 2018-03-07 2025-08-05 Transgene Recombinant pseudocowpoxvirus
AU2019412516A1 (en) 2018-12-28 2021-07-15 Transgene M2-defective poxvirus
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1993005182A1 (en) 1991-09-05 1993-03-18 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
WO1994025588A2 (en) 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
DE69433520T2 (de) * 1993-07-10 2004-11-11 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-nukleinsäure enthaltende pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zelltod, und zur behandlung von neoplasmen
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
EP0722342B1 (en) * 1993-09-20 2004-12-29 The Trustees Of The University Of Pennsylvania REGULATION OF bcl-2 GENE EXPRESSION
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
CA2256305A1 (en) 1996-05-22 1997-11-27 Mcgill University Specific inhibitors of dna methyltransferase enzyme
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5965420A (en) * 1997-03-05 1999-10-12 Smithkline Beecham Corporation Human protein kinases hYAK3
ATE432348T1 (de) * 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
WO1999012027A1 (en) 1997-08-29 1999-03-11 The Regents Of The University Of California Modulators of dna cytosine-5 methyltransferase and methods for use thereof
DE69837094T2 (de) * 1997-09-05 2007-08-30 The Regents Of The University Of California, Oakland Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6060310A (en) * 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6020475A (en) 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
EP1067956B1 (en) * 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6166239A (en) 1998-09-04 2000-12-26 Isis Pharmaceuticals, Inc. Oligonucleotide protecting groups
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
WO2000021556A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
JP2002542015A (ja) 1999-04-19 2002-12-10 エンゲルハード・コーポレーシヨン セリアと白金族金属を含んで成る触媒組成物
WO2001051061A1 (en) * 2000-01-14 2001-07-19 Intrabiotics Pharmaceuticals, Inc. Derivatives of polyene macrolides and preparation and use thereof

Also Published As

Publication number Publication date
EP1162982B9 (fr) 2005-07-06
ATE288759T1 (de) 2005-02-15
FR2790955A1 (fr) 2000-09-22
EP1162982A2 (fr) 2001-12-19
DK1162982T3 (da) 2005-06-13
JP2002539265A (ja) 2002-11-19
WO2000056342A2 (fr) 2000-09-28
EP1162982B1 (fr) 2005-02-09
PT1162982E (pt) 2005-05-31
AU3300600A (en) 2000-10-09
CA2371990A1 (fr) 2000-09-28
US20020192184A1 (en) 2002-12-19
ES2235839T3 (es) 2005-07-16
DE60018050D1 (de) 2005-03-17
WO2000056342A3 (fr) 2001-07-26
US7700569B1 (en) 2010-04-20
DE60018050T2 (de) 2006-02-23
US7108844B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
FR2790955B1 (fr) Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
BR0111438A (pt) Análogos de ácido barbitúrico como agentes terapeuticos
HUP0104573A2 (hu) Agrokémiai készítmények
NO995819D0 (no) Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
MX9700885A (es) Nuevas heteroariloxazolidinonas.
DK1390378T3 (da) Farmaceutisk aktive uridin estere
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
HU9501623D0 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an antidepressant drug
IT1226727B (it) Farmaci precursori della dopamina.
PL369999A1 (en) 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
IT1318667B1 (it) Medicamento antinfiammatorio.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
NZ527230A (en) Crystal form of a cyclic depsipeptide having improved activity
IT1312569B1 (it) Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
EP1062948A4 (en) DRUGS AGAINST CARDIAC DIASTOLIC DISORDERS
ATE308984T1 (de) Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen
MXPA03009723A (es) Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo.
ATE275551T1 (de) Halogenpyrimidine
DE50010009D1 (en) Hydroxamsäurederivate
ES2179668T3 (es) Un compuesto wf002, su produccion y su uso.
CA2353909A1 (en) Betacellulin muteins

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 17

ST Notification of lapse

Effective date: 20161130